Comparison of outcomes between early follicular phase long-acting long protocol and antagonist protocol in of patients with normal ovarian reserve: a randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087419

Enrollment

Unknown

Registered

2024-07-26

Start date

2024-08-01

Completion date

Unknown

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

early follicular phase long-acting long protocol:early follicular phase long-acting long protocol for controlled ovarian stimulation

antagonist group:antagonist protocol for controlled ovarian stimualtion

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) At least one IVF assisted pregnancy indication should be present: tubal factors, male factors, ovulation disorders in non polycystic ovary syndrome. 2) Normal ovarian reserve (basal FSH = 10mIU/ml and AFC 7-24 or AMH = 1.2ng/ml). 3) Age range from 20 to 40 years old (including boundaries). 4) The menstrual cycle is defined as 21-35 days. 5) Body mass index 18-28 Kg/M2 6) 1-2 IVF/ICSI-ET treatments. 7) Informed consent for this study.

Exclusion criteria

Exclusion criteria: 1) Patients with contraindications to assisted reproductive technology or pregnancy. 2) Patients with uterine abnormalities that affect pregnancy based on clinical experience, such as uterine malformations (unicorn uterus, bicornuate uterus, bicornuate uterus, mediastinal uterus); Adenomyosis of the uterus; Patients with uterine fibroids (fibroids larger than 3cm or closely related to the endometrium); Submucosal uterine fibroids; Moderate to severe intrauterine adhesions; Untreated endometrial polyps, etc. 3) Due to various factors, frozen embryo transfer is planned for this cycle (such as hydrosalpinx, PGD or PGS patients). 4) History of recurrent miscarriage. 5) Patients with polycystic ovary syndrome. 6) Endometriosis stage III-IV. 7) Unilateral ovarian patients. 8) Either spouse has chromosomal abnormalities. 9) People with habits of alcoholism, smoking, and drug abuse. 10) Patients participating in other clinical studies.

Design outcomes

Primary

Measure	Time frame
live birth rate per initiated cycle;	—

Secondary

Measure	Time frame
clinical pregnancy rate;incidence of moderate/severe OHSS;miscarriage rate;live birth rate per embryo transfer cycle;cumulative live birth rate;ectopic pregnancy rate;implantation rate;fertilization rate;cleavage rate;good quality embryo rate;blastocyst formation rate;Average treatment cost;treatment cycle cancel rate;number of oocytes retrievaled;	—

Countries

China

Contacts

Public ContactQiongfang Wu

Jiangxi Maternal and Child Health Hospital

wuqiongfang898@sina.com+86 139 7001 7651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026